Overview of current advances in and future approaches to CLL management with BTK and Bcl-2 inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.

Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).

Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).